JP2011519941A - ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 - Google Patents

ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 Download PDF

Info

Publication number
JP2011519941A
JP2011519941A JP2011508584A JP2011508584A JP2011519941A JP 2011519941 A JP2011519941 A JP 2011519941A JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011519941 A JP2011519941 A JP 2011519941A
Authority
JP
Japan
Prior art keywords
compound
erbb
cancer
lapatinib
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519941A5 (enExample
Inventor
トナ、エム．ギルマー
ジェームズ、ジー．グレガー、ジュニア
リ、リウ
ホン、シ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011519941(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2011519941A publication Critical patent/JP2011519941A/ja
Publication of JP2011519941A5 publication Critical patent/JP2011519941A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011508584A 2008-05-05 2009-05-05 ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 Pending JP2011519941A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05
US61/050,322 2008-05-05
PCT/US2009/042768 WO2009137429A1 (en) 2008-05-05 2009-05-05 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor

Publications (2)

Publication Number Publication Date
JP2011519941A true JP2011519941A (ja) 2011-07-14
JP2011519941A5 JP2011519941A5 (enExample) 2012-06-21

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508584A Pending JP2011519941A (ja) 2008-05-05 2009-05-05 ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法

Country Status (19)

Country Link
US (3) US20090274693A1 (enExample)
EP (1) EP2274304A4 (enExample)
JP (1) JP2011519941A (enExample)
KR (1) KR20110004462A (enExample)
CN (1) CN102083824A (enExample)
AR (1) AR071631A1 (enExample)
AU (1) AU2009244453B2 (enExample)
BR (1) BRPI0912582A2 (enExample)
CA (1) CA2723699A1 (enExample)
CL (1) CL2009001063A1 (enExample)
EA (1) EA020779B1 (enExample)
IL (1) IL209057A0 (enExample)
MX (1) MX2010012101A (enExample)
PE (1) PE20091832A1 (enExample)
SG (1) SG190623A1 (enExample)
TW (1) TW201006829A (enExample)
UY (1) UY31800A (enExample)
WO (1) WO2009137429A1 (enExample)
ZA (1) ZA201007722B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518506A (ja) * 2019-01-25 2022-03-15 エグゼリクシス， インコーポレイテッド キナーゼ依存性障害の治療のための化合物

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
TW201106972A (en) * 2009-07-27 2011-03-01 Genentech Inc Combination treatments
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR101806323B1 (ko) * 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
SG191230A1 (en) * 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
TW201309650A (zh) 2011-02-10 2013-03-01 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EP2704717A1 (en) * 2011-05-02 2014-03-12 Exelixis, Inc. Method of treating cancer and bone cancer pain
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
EA023521B1 (ru) 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
CN108341873B (zh) * 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
SG11201404505PA (en) 2012-01-31 2014-10-30 Daiichi Sankyo Co Ltd Pyridone derivative
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
US10196446B2 (en) 2013-10-14 2019-02-05 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
HUE049437T2 (hu) 2014-02-04 2020-09-28 Astellas Pharma Inc Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
NZ725361A (en) * 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
WO2016104617A1 (ja) 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
WO2017223180A2 (en) 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
KR102571911B1 (ko) 2017-01-26 2023-08-28 오노 야꾸힝 고교 가부시키가이샤 퀴놀린 유도체의 에탄술폰산염
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523680A (ja) * 2007-04-13 2010-07-15 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド ＥｒｂＢ療法に耐性である癌を治療するための方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1962903B1 (en) * 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
WO2007081978A2 (en) * 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
WO2008076415A1 (en) * 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
ES2541051T3 (es) * 2007-05-17 2015-07-15 Genentech, Inc. Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523680A (ja) * 2007-04-13 2010-07-15 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド ＥｒｂＢ療法に耐性である癌を治療するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013053617; Ｆ．Ｅｃｋｅｌ　ｅｔ　ａｌ．，　Ｅｘｐｅｒｔ　Ｏｐｉｎｉｏｎ　ｏｎ　Ｅｍｅｒｇｉｎｇ　Ｄｒｕｇｓ，　２００７，　１２（４），　ｐｐ５７１-５８９ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518506A (ja) * 2019-01-25 2022-03-15 エグゼリクシス， インコーポレイテッド キナーゼ依存性障害の治療のための化合物
JP7556865B2 (ja) 2019-01-25 2024-09-26 エグゼリクシス， インコーポレイテッド キナーゼ依存性障害の治療のための化合物

Also Published As

Publication number Publication date
ZA201007722B (en) 2011-08-31
US20130150363A1 (en) 2013-06-13
AR071631A1 (es) 2010-06-30
EP2274304A4 (en) 2012-05-30
WO2009137429A1 (en) 2009-11-12
AU2009244453A1 (en) 2009-11-12
PE20091832A1 (es) 2009-12-25
EA201071268A1 (ru) 2011-06-30
SG190623A1 (en) 2013-06-28
CL2009001063A1 (es) 2010-09-24
BRPI0912582A2 (pt) 2015-07-28
US20090274693A1 (en) 2009-11-05
US20130142790A1 (en) 2013-06-06
UY31800A (es) 2009-11-10
CN102083824A (zh) 2011-06-01
CA2723699A1 (en) 2009-11-12
TW201006829A (en) 2010-02-16
MX2010012101A (es) 2010-11-30
KR20110004462A (ko) 2011-01-13
IL209057A0 (en) 2011-01-31
EA020779B1 (ru) 2015-01-30
AU2009244453B2 (en) 2012-07-19
EP2274304A1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
AU2009244453B2 (en) Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor
JP6282296B2 (ja) Ｅｇｆｒを標的とする癌の組み合わせ治療方法
JPWO2020130125A1 (ja) 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US10011659B2 (en) Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
KR20100131446A (ko) Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도
JP2022027658A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
US20210260064A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
EP3176183A1 (en) Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US20140056910A1 (en) Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
WO2022053697A1 (en) Fgfr inhibitor combination therapies
Wang et al. Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
WO2025127108A1 (ja) Ｎ－（４－（４－アミノ－６－エチニル－５－（キノリン－３－イル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－７－イル）ビシクロ［２．２．１］ヘプタン－１－イル）－５－メチルピラジン－２－カルボキサミド又はその塩を有効成分とする脳移行性腫瘍治療剤
HK40044450A (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150331